Electric field brain cancer treatment gains support in China

14 May 2020
zai_lab_large

The Chinese regulator has approved a submission from Novocure (Nasdaq: NVCR) and Shanghai’s Zai Lab (Nasdaq: ZLAB) for Optune (tumor treating fields), a novel electric field-based therapy.

The approval covers the treatment of glioblastoma (GBM) in the first-line setting, in combination with temozolomide (TMZ). Optune is also approved as a monotherapy for the treatment of people with recurrent GBM.

GBM is the most common form of primary brain cancer, and Optune is the first treatment in this indication to be approved in China in over 15 years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical